Page last updated: 2024-12-07

eudragit rl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Eudragit RL is a synthetic, enteric polymer commonly used in pharmaceutical formulations. It is a copolymer of methacrylic acid and methyl methacrylate, with a high molecular weight. It exhibits pH-dependent solubility, meaning it dissolves in the alkaline environment of the small intestine but not in the acidic environment of the stomach. This property makes it ideal for protecting sensitive drugs from degradation in the stomach and for targeted drug delivery to the small intestine. Eudragit RL is typically used to create enteric coatings for tablets, capsules, and granules. These coatings are designed to dissolve only after the dosage form has passed through the stomach, releasing the drug in the small intestine.

Eudragit RL is frequently studied for its ability to enhance the bioavailability of certain drugs, reduce side effects, and improve drug delivery efficiency. The research focuses on understanding the release kinetics, stability, and compatibility of Eudragit RL coatings in different formulations. It also examines the impact of different manufacturing processes on the properties of the polymer and the effectiveness of the final drug product.

Eudragit RL is considered a safe and effective excipient for use in pharmaceutical formulations. It is widely used in the pharmaceutical industry to enhance the therapeutic efficacy of a range of drugs.'

Cross-References

ID SourceID
PubMed CID104804
MeSH IDM0163508

Synonyms (6)

Synonym
eudragit rl
51822-44-7
eudragit retard l
2-methylprop-2-enoic acid--n,n-dimethylmethanamine (2/1)
DTXSID80966155
n,n-dimethylmethanamine;2-methylprop-2-enoic acid

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, Eudragit RS and Eudragit RL in combination with inulin made free films which had more swelling and permeation of drug in the colonic medium rather than the other media."( Permeability and swelling studies on free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery.
Afrasiabi Garekani, H; Akhgari, A; Farahmand, F; Sadeghi, F; Vandamme, TF, 2006
)
0.63

Bioavailability

ExcerptReferenceRelevance
" Taking into account probability values of absorption, active principle release and absorption of product have been properly controlled and so optimal bioavailability of the preparation can be expected."( [Preformulation study of controlled release nitrofurantoin preparations. 2].
Antal, I; Marton, S; Rácz, I, 1990
)
0.28
"01 IU/mL and an average aPTT of 24 seconds (2-fold increase) were obtained 7 hours after oral dosing of Eudragit RL/PCL NPs containing heparin, exhibiting an absolute bioavailability of 23%."( In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits.
Hoffman, M; Jiao, Y; Lecompte, T; Maincent, P; Marchand-Arvier, M; Ubrich, N; Vigneron, C, 2002
)
0.53
" These systems should also provide postruminal bioavailability and controlled release of the active ingredient."( Bilayer tablets based on poly (epsilon-caprolactone) and polymethylmethacrilates as controlled-release systems for ruminants.
Gavini, E; Giunchedi, P; Sanna, V, 2004
)
0.32
" Based on comparison of the area under the blood concentration-time curve values, the relative bioavailability of CyA from each nanoparticulate formulation ranged from 20 to 35%."( Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles.
Bodmeier, R; Hoffman, M; Maincent, P; Schmidt, C; Ubrich, N, 2005
)
0.33
"The objective of the present study is to develop microspheres for celecoxib to enhance its bioavailability by increasing its gastric residence time."( Development and evaluation of a gastroretentive drug delivery system for the low-absorption-window drug celecoxib.
Ahuja, A; Ali, J; Baboota, S; Hasan, S; Tyagi, P,
)
0.13
"A gastro retentive floating drug delivery system with multiple-unit minitab's based on gas formation technique was developed in order to prolong the gastric residence time and to increase the overall bioavailability of the drug."( Preparation of a matrix type multiple-unit gastro retentive floating drug delivery system for captopril based on gas formation technique: in vitro evaluation.
Chinnala, KM; Kesavan, B; Meka, L; Vobalaboina, V; Yamsani, MR, 2008
)
0.35
" The relative bioavailability of the sustained-release pellets was studied in six beagle dogs after oral administration in a fast state using a commercially available immediate release tablet as a reference."( Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs.
He, HB; Huang, HF; Lu, Y; Tang, X, 2008
)
0.35
" The type of solvent did not distinctly influence the particle properties or insulin stability but modified significantly the performance in vivo in rats, NPs prepared with glycofurol led to a bioavailability of F=1."( Oral insulin delivery in rats by nanoparticles prepared with non-toxic solvents.
Béduneau, A; Javot, L; Lamprecht, A; Pellequer, Y; Viehof, A, 2013
)
0.39

Dosage Studied

Eudragit RL (ERL) and RS (ERS) are polymethacrylate co-polymers. They are used in film coating of sustained release dosage forms. ERL contains more of quaternary ammonium groups (QAG) than ERS.

ExcerptRelevanceReference
" The effects of different polymer ratios of Eudragit RS30D and Eudragit RL30D, different particle sizes, and different combination of various formulations of solid dispersions on the in vitro release kinetics of drugs from the dosage forms were investigated."( Development of extended-release solid dispersions of nonsteroidal antiinflammatory drugs with aqueous polymeric dispersions: optimization of drug release via a curve-fitting technique.
Ho, C; Hwang, GC, 1992
)
0.52
"A colorimetric ion-pair complexation method has been developed which provides a simple and rapid way of quantifying Eudragit RS100 and RL100 in pharmaceutical dosage forms."( A simple and rapid method for the quantification of Eudragit RS100 and RL100 poly(methacrylates) in sustained-release dosage forms.
Hansraj, BR; Khan, KA; Melia, CD; Wilding, IR, 1991
)
0.28
"Eudragit RL and RS 30D are pseudolatexes frequently used in the coating of solid dosage forms."( The influence of buffer species and strength on diltiazem HCl release from beads coated with the aqueous cationic polymer dispersions, Eudragit RS, RL 30D.
Bodmeier, R; Guo, X; Sarabia, RE; Skultety, PF, 1996
)
1.74
"01 IU/mL and an average aPTT of 24 seconds (2-fold increase) were obtained 7 hours after oral dosing of Eudragit RL/PCL NPs containing heparin, exhibiting an absolute bioavailability of 23%."( In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits.
Hoffman, M; Jiao, Y; Lecompte, T; Maincent, P; Marchand-Arvier, M; Ubrich, N; Vigneron, C, 2002
)
0.53
"Eudragit RL (ERL) and RS (ERS) are polymethacrylate co-polymers, used in film coating of sustained release dosage forms, possessing some hydrophilic properties due to the presence of quaternary ammonium groups (QAG), where ERL contains more of such groups, hence more permeable, than ERS."( Lactic acid-induced modifications in films of Eudragit RL and RS aqueous dispersions.
Abd-Elbary, A; El-Samaligy, M; Omari, DM; Sallam, A, 2004
)
2.02
"4, to study the release behavior of the dosage forms in the intestinal environment."( Bilayer tablets based on poly (epsilon-caprolactone) and polymethylmethacrilates as controlled-release systems for ruminants.
Gavini, E; Giunchedi, P; Sanna, V, 2004
)
0.32
" These aqueous colloidal dispersions of polymeric materials for oral administration are intended for film coating of solid dosage forms or for direct manufacturing of nanoparticles."( Preparation of surfactant-free nanoparticles of methacrylic acid copolymers used for film coating.
Allémann, E; Doelker, E; Fessi, H; Gurny, R; Konan-Kouakou, YN; Nguyen, CA; Quintanar-Guerrero, D, 2006
)
0.33
"Film forming polymeric solutions may present an alternative to the common transdermal dosage forms such as patches or gels."( Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs.
Franke, P; Lehr, CM; Schaefer, UF; Zurdo Schroeder, I, 2007
)
0.34
" The release rate of theophylline decreased significantly over time from pellets coated with an acrylic dispersion containing 10% albumin when there was no acidification of the acrylic dispersion; however, when pellets were coated with an acidified EUDRAGIT/albumin dispersion, the theophylline release rate was stable for dosage forms stored in the absence of humidity."( Use of proteins to minimize the physical aging of EUDRAGIT sustained release films.
Infeld, MH; Kucera, SA; Malick, AW; McGinity, JW; Shah, NH; Zheng, W, 2007
)
0.34
" The compression of these particles into tablets revealed that desirable controlled released dosage forms could be prepared."( Preparation of functional composite particles of salbutamol sulfate using a 4-fluid nozzle spray-drying technique.
Chen, R; Danjo, K; Okamoto, H, 2008
)
0.35
" Stability study of pellets was performed as capsule dosage form in aluminium-PVDC packaging mode at room temperature, 40 degrees C, 40 degrees C/75%RH & 30 degrees C/70%RH for three months."( Stability study of ambroxol hydrochloride sustained release pellets coated with acrylic polymer.
Islam, KM; Jalil, RU; Kibria, G, 2009
)
0.35
" The obtained new insight into the occurring drug-polymer interactions can help to facilitate the development/optimisation of this type of dosage forms."( Characterisation of quaternary polymethacrylate films containing tartaric acid, metoprolol free base or metoprolol tartrate.
Glaessl, B; Rades, T; Siepmann, F; Siepmann, J; Tucker, I, 2009
)
0.35
" The obtained new insight into the underlying drug release mechanisms in Eudragit RL networks can help to facilitate the optimisation of this type of dosage forms."( Deeper insight into the drug release mechanisms in Eudragit RL-based delivery systems.
Glaessl, B; Rades, T; Siepmann, F; Siepmann, J; Tucker, I, 2010
)
0.84
"Ammonio methacrylate copolymers Eudragit(®) RS PO and Eudragit® RL PO have found widespread use as key components in various types of extended release solid dosage forms."( Investigation of the physical-mechanical properties of Eudragit(®) RS PO/RL PO and their mixtures with common pharmaceutical excipients.
Dave, VS; Fahmy, RM; Hoag, SW, 2013
)
0.39
" With the dissolution test for delayed-release solid dosage forms (Ph."( Coatings from blends of Eudragit® RL and L55: a novel approach in pH-controlled drug release.
Leopold, CS; Wulff, R, 2014
)
0.4
" Pellets are a dosage form that is frequently used in such formulations."( A study on the applicability of in-line measurements in the monitoring of the pellet coating process.
Hudovornik, G; Korasa, K; Vrečer, F, 2015
)
0.42
" The aim of this study was to obtain information on the drug release mechanism of solid dosage forms coated with blends of Eudragit® RL (RL) and Eudragit® L-55 (L55)."( Coatings of Eudragit® RL and L-55 Blends: Investigations on the Drug Release Mechanism.
Leopold, CS; Wulff, R, 2016
)
0.43
" In this study, fluid bed coating is proposed for the production of controlled release dosage forms of glass solutions by applying a second, rate controlling membrane on top of the glass solution."( Controlling the Release of Indomethacin from Glass Solutions Layered with a Rate Controlling Membrane Using Fluid-Bed Processing. Part 1: Surface and Cross-Sectional Chemical Analysis.
Dereymaker, A; Roberts, CJ; Scurr, DJ; Steer, ED; Van den Mooter, G, 2017
)
0.46
" For the first time, the co-ordinated use of fused deposition modelling (FDM), 3D printing and liquid dispensing to fabricate individualised dosage form on demand in a fully automated fashion has been demonstrated."( On demand manufacturing of patient-specific liquid capsules via co-ordinated 3D printing and liquid dispensing.
Alhnan, MA; Gollwitzer, V; Habashy, R; Okwuosa, TC; Soares, C; Timmins, P, 2018
)
0.48
" In particular, when printing sustained release solid dosage forms, as for instance implants, inserts, and also tablets, estimation of the drug release profile in vivo is necessary."( 3D-Printed Network Structures as Controlled-Release Drug Delivery Systems: Dose Adjustment, API Release Analysis and Prediction.
Korte, C; Quodbach, J, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (95)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.05)18.7374
1990's7 (7.37)18.2507
2000's37 (38.95)29.6817
2010's46 (48.42)24.3611
2020's4 (4.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.90 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index5.60 (4.65)
Search Engine Demand Index46.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.93%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other107 (99.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]